Chelsea Green Publishing

Online Catalogs & Media Site

The LDN Book

How a Little-Known Generic Drug — Low Dose Naltrexone — Could Revolutionize Treatment for Autoimmune Diseases, Cancer, Autism, Depression, and More

Health & Wellness

How can it be that a generic drug—administered off-label in small daily doses and proven to help people suffering from a wide variety of autoimmune diseases and cancers—still languishes in medical obscurity?

Low Dose Naltrexone (LDN) is an active opioid antagonist and works by partially blocking opioid receptors that, in turn, helps to balance your immune system by tricking your body into producing more endorphins. While not for everyone, this generic drug is extremely affordable and presents few known or serious side effects. Administered off-label in small daily doses (0.5 to 4.5 mg), it is being used around the world to help people suffering from a range of ailments including multiple sclerosis, lupus, thyroiditis, inflammatory bowel disease, and various cancers, as well as autism spectrum disorder, chronic fatigue, and depression.

The LDN Book explains the drug’s origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world’s largest LDN charity organization with more than 19,000 members worldwide. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. She has helped connect thousands of people to this potential remedy to their ailments.

With information from nearly a dozen medical professionals on LDN’s efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.


“I first came across LDN several years ago when a medical colleague said I should look into its positive effects in patients with MS, Crohn’s disease, and other autoimmune disorders. I was so impressed with what I read that I helped submit a petition to the UK government to ask for funding for further research into this inexpensive drug. But, as with so many petitions, no progress was made. I hope The LDN Book—which presents up-to-date findings that again confirm the efficacy of this safe, cheap, generic drug in helping to control many chronic, disabling conditions—is read by those in the Department of Health and by all doctors caring for patients with autoimmune disease. In the UK, LDN has been stranded in limbo; maybe now the time has come for it to be accepted as a recognized therapy that could, at least, be tried on those suffering such long-term diseases of the immune system.”--Dr. Chris Steele, MBE, general practitioner; medical presenter on ITV’s This Morning

“As a practicing physician who has used LDN as a cornerstone therapy for over fifteen years, I can say without equivocation that LDN is the most important and successful medicine I have ever used. I often joke that if not for LDN I couldn’t pay my mortgage; I’ve had so many new patients referred to me by someone whose life has improved dramatically through the use of LDN. And despite my knowledge and experience with LDN, I’ve learned a great deal from The LDN Book—aspects of its basic science I hadn’t known, new uses, and how its uses can inform us about the causes of various diseases. This is a wonderful book for any patient with an autoimmune disease, cancer, depression, or a host of other conditions and is a must-read for any physician whose goal is to help their patients.”--Dr. Thomas Cowan, author of The Fourfold Path to Healing and coauthor of The Nourishing Traditions Book of Baby & Child Care

“Low Dose Naltrexone (LDN) was discovered by my husband and partner, Dr. Bernard Bihari. Incredibly informative and superbly written by various members of the medical profession sharing their experiences using this extraordinary drug, The LDN Book honors his legacy in helping patients suffering from autoimmune and other diseases to regain their health and their lives.”--Jacqueline Young


Linda Elsegood

Linda Elsegood

Linda Elsegood is the founder of the LDN Research Trust, which was set up in the UK as a Registered Charity in 2004, and is the editor of The LDN Book. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN.


Linda Elsegood Facebook
LDN Research Trust Website
LDN Research Trust Twitter
LDN Research Trust on Health Unlocked
Linda Elsegood on Pinterest
Linda Elsegood on Google+
LDN Research Trust on Vimeo


Linda Elsegood's MS, LDN and the LDN Research Trust Interview

Linda Elsegood's MS, LDN and the LDN Research Trust interview

Jackie Young-Bihari - Widow of Dr Bernard Bihari - LDN

Jackie Young-Bihari - Widow of Dr Bernard Bihari - LDN

The LDN Book

Pages:240 pages
Book Art:Black-and-white illustrations throughout
Size: 6 x 9 inch
Publisher:Chelsea Green Publishing
Paperback: 9781603586641
Pub. Date February 15, 2016

Available In/Retail Price

Paperback, 240 pages, $27.99